Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis

PLoS One. 2022 Jul 6;17(7):e0270627. doi: 10.1371/journal.pone.0270627. eCollection 2022.

Abstract

Although advanced age and presence of comorbidities significantly impact the variation observed in the clinical symptoms of COVID-19, it has been suggested that genetic variants may also be involved in the disease. Thus, the aim of this study was to perform a systematic review with meta-analysis of the literature to identify genetic polymorphisms that are likely to contribute to COVID-19 pathogenesis. Pubmed, Embase and GWAS Catalog repositories were systematically searched to retrieve articles that investigated associations between polymorphisms and COVID-19. For polymorphisms analyzed in 3 or more studies, pooled OR with 95% CI were calculated using random or fixed effect models in the Stata Software. Sixty-four eligible articles were included in this review. In total, 8 polymorphisms in 7 candidate genes and 74 alleles of the HLA loci were analyzed in 3 or more studies. The HLA-A*30 and CCR5 rs333Del alleles were associated with protection against COVID-19 infection, while the APOE rs429358C allele was associated with risk for this disease. Regarding COVID-19 severity, the HLA-A*33, ACE1 Ins, and TMPRSS2 rs12329760T alleles were associated with protection against severe forms, while the HLA-B*38, HLA-C*6, and ApoE rs429358C alleles were associated with risk for severe forms of COVID-19. In conclusion, polymorphisms in the ApoE, ACE1, TMPRSS2, CCR5, and HLA loci appear to be involved in the susceptibility to and/or severity of COVID-19.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoproteins E
  • COVID-19* / genetics
  • Genetic Predisposition to Disease*
  • HLA-A Antigens
  • Humans
  • Polymorphism, Genetic

Substances

  • Apolipoproteins E
  • HLA-A Antigens

Grants and funding

This study was partially supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grant numbers 401610/2020-9 and 425579/2018-2), Fundo de Incentivo à Pesquisa e Eventos (FIPE) at Hospital de Clínicas de Porto Alegre (grant number: 2020-0218), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). D.C., C.B.L. and N.E.L are recipients of a scholarship from CNPq, while C.D. is a recipient of scholarship from CAPES.